In Brief: Summit Technology
This article was originally published in The Gray Sheet
Executive Summary
Summit Technology: Second quarter (ended June 30) revenues are $18 mil., with "significant contributions" coming from its Lens Express subsidiary and patent licensing fees, the company says July 3. The Waltham, Massachusetts firm notes that revenues from excimer laser equipment sales for the quarter "were substantially lower" than the prior-year quarter, attributing the shortfall to "the large number of systems installed in the U.S. since FDA approval" of its system for photorefractive keratectomy in October 1995 as well as competition from Visx, which received approval for its PRK system in March. Summit estimates an overall loss for the quarter of approximately $11-12 mil. The company's stock, which has lost nearly 70% of its value since the end of 1995, was off 3-1/2 points to 10-3/4 in NASDAQ trading July 3...
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.